Metamorphopsia is a common symptom in different macular disorders. Micropsia and macropsia are special types of metamorphopsia. Recent theories suggest that both retinal and cortical mechanisms are involved in the development and changes of metamorphopsia. Different functional tests have been proposed for the evaluation of metamorphopsia: from the Amsler grid to the hand-held mobile devices for home monitoring. This review addresses some new insights into the pathophysiology of metamorphopsia and different available tests for the evaluation of this symptom in most common macular disorders. The importance of quantification of metamorphopsia in macular diseases is confirmed by the most recent therapeutic approaches.

Keywords:
Macular disease , Age-related macular degeneration, Visual function, Vitreoretinal interface disorder, Diabetic retinopathy, Central serous chorioretinopathy, Metamorphopsia
1.
Wiecek E, Lashkari K, Dakin SC, Bex P: Novel quantitative assessment of metamorphopsia in maculopathy. Invest Ophthalmol Vis Sci 2014;56:494-504.
2.
Amsler M: L'Examen qualitatif de la fonction maculaire. Ophthalmologica 1947;114:248-261.
3.
Forster R: Metamorphopsie. Ein Symptom partieller Schrumpfung der Retina (Retinitis circumscripta). Berlin, Ophthalmologische Beiträge, 1862.
4.
Knapp H: Ueber isolirte Zerreissungen der Aderhaut in Folge von Traumen auf dem Augapfel. Arch Augenheilk 1869;1:6-29.
5.
Wundt W: Zur Theorie der raumlichen Gesichtswahrnehmungen. Philosophische Studien 1898;14:1.
6.
Amsler M: Quantitative and qualitative vision. Trans Ophthalmol Soc UK 1949;69:397-410.
7.
Amsler M: Earliest symptoms of diseases of the macula. Br J Ophthalmol 1953;37:521-537.
8.
Mackay G: On blinding of the retina by direct sunlight; a study in prognosis. Ophthal Rev 1984;13:1-20, 41-57, 83-96.
9.
Oguchi C: Eine besondere Form von Chorioretinitis centralis nebst Bemerkungen über nachbildartiges Skotom. Albrecht von Graefes Archive für Ophthalmologie 1922;110:25.
10.
Kitahara S: Ueber klinische Beobachtungen bei der in Japan häufig vorkommenden Chorioretinitis centralis serosa. Klin Mbl Augenheilk 1936;97:345.
11.
Horniker A: Su di una forma di retinite centrale di origine vasoneurotica. Ann Ottal 1927;55:578.
12.
Bruckner R, Field NH: Beitrag zum Symptomenkomplex der Chorioretinitis centralis serosa. Ophthalmologica 1945;109:281.
13.
Watanabe A, Arimoto S, Nishi O: Correlation between metamorphopsia and epiretinal membrane optical coherence tomography findings. Ophthalmology 2009;116:1788-1793.
14.
Okamoto F, Sugiura Y, Okamoto Y, Hiraoka T, Oshika T: Associations between metamorphopsia and foveal microstructure in patients with epiretinal membrane. Invest Ophthalmol Vis Sci 2012;53:6770-6775.
15.
Ponsioen TL, Hooymans JL, Hols LI: Remoddeling of the human vitreous and vitreoretinal interface-a dynamic process. Progr Retin Eye Res 2010;29:580-595.
16.
Agte S, Junke S, Matthias S, Ulbricht E, Erdmann I, Wurm A, Schild D, Kas JA, Reichenbach A: Müller glial cell-provided cellular light guidance through the vital guinea pig retina. Biophys J 2011;101:2611-2619.
17.
Schuchard RA: Validity and interpretation of Amsler grid reports. Arch Ophthalmol 1993;111:776-780.
18.
Wall M, May DR: Threshold Amsler grid testing in maculopathies. Ophthalmology 1987;94:1126-1133.
19.
Boldrey EE: Foveal ablation for subfoveal choroidal neovascularization. Ophthalmology 1989;96:1430-1436.
20.
Walsh AW, Magargal LE, Wright F, Donoso LA: The early natural history of subfoveal neovascular membranes in eyes with age-related macular degeneration. Ann Ophthalmol 1989;21:348-350.
21.
Swann PG, Lovie-Kitchin JE: Age-related maculopathy. II: the nature of the central visual field loss. Ophthalmic Physiol Opt 1991;11:59-70.
22.
Natsikos VE, Dean Hart JC: Static perimetric and Amsler chart changes in patients with idiopathic central serous retinopathy. Acta Ophthalmol 1980;58:908-917.
23.
Easterbrook M: The use of Amsler grids in early chloroquine retinopathy. Ophthalmology 1984;91:1368-1372.
24.
Easterbrook M: The sensitivity of Amsler grid testing in early chloroquine retinopathy. Trans Ophthalmol Soc UK 1985;104:204-207.
25.
Wall M, Collins C, May DR: Low-intensity grids improve sensitivity of Amsler grid testing in diabetic patients without background retinopathy. Ann Ophthalmol 1990;22:96-100.
26.
Ruiz RS, Saatci OA: Chloroquine and hydroxychloroquine retinopathy: how to follow affected patients. Ann Ophthalmol 1991;23:290-291.
27.
Wolfe KA, Sadun AA: Threshold Amsler grid testing in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 1991;229:219-223.
28.
Bernstein HN: Ocular safety of hydroxychloroquine. Ann Ophthalmol 1991;23:292-296.
29.
Zygulska-Mach H, Starzycka M, Ciechanowska A: Retinal function after surgical treatment of detachment. Ophthalmologica 1979;178:210-214.
30.
Kreissig I, Lincoff H, Witassek B, Kolling G: Color vision and other parameters of macular function after retinal reattachment. Dev Ophthalmol 1981;2:77-85.
31.
Smith RG, Hardman Lea SJ, Galloway NR: Visual performance in idiopathic macular holes. Eye 1990;4:190-194.
32.
Wall M, Sadun AA: Threshold Amsler grid testing. Cross-polarizing lenses enhance yield. Arch Ophthalmol 1986;104:520-523.
33.
Yannuzzi LA: A modified Amsler grid. A self-assessment test for patients with macular disease. Ophthalmology 1982;89:157-159.
34.
Grand MG, Burgess DB, Singerman LJ, Ramsey J: Choroidal osteoma. Retina 1984;4:84-89.
35.
Fine SL: Early detection of extrafoveal neovascular membranes by daily central field evaluation. Ophthalmology 1985;92:603-609.
36.
Folk JC: Aging macular degeneration. Ophthalmology 1985;92:603-609.
37.
Singerman LJ: Important points in management in patients with choroidal neovascularization. Ophthalmology 1985;92:610-614.
38.
Fine AM, Elman MJ, Ebert JE, Prestia PA, Starr JS, Fine SL: Earliest symptoms caused by neovascular membranes in the macula. Arch Ophthalmol 1986;104:513-514.
39.
Chang MA, Morgan CM, Schatz H: The Amsler grid. Retina 1987;7:279.
40.
Morrison DL, Magargal LE, Ehrlich DR, Goldberg RE, Robb-Doyle E: Review of choroidal osteoma: successful krypton red laser photocoagulation of an associated subretinal neovascular membrane involving the fovea. Ophthalmic Surg 1987;18:299-303.
41.
Achard OA, Safran AB, Duret FC, Ragama E: Role of the completion phenomenon in the evaluation of Amsler grid results. Am J Ophthalmol 1995;120:322-329.
42.
Parkes L, Lund J, Angelucci A, Solomon JA, Morgan M: Compulsory averaging of crowded orientation signals in human vision. Nat Neurosci 2001;4:739-744.
43.
Ramachandran VS, Gregory RL: Perceptual filling in of artificially induced scotomas in human vision. Nature 1991;350:699-702.
44.
Heinen SJ, Skavenski AA: Recovery of visual responses in foveal VI neurons following bilateral foveal lesions in adult monkey. Exp Brain Res 1991;83:670-674.
45.
Gilbert CD, Wiesel TN: Receptive field dynamics in adult primary visual cortex. Nature 1992;356:150-152.
46.
Shinoda K, Ishida S, Kawashima S, Matsuzaki T, Yamada K, Katsura H: A new method for quantification of metamorphopsia in patients with epiretinal membrane. Jpn J Ophthalmol 2000;44:424-427.
47.
Bouwens MD, Van Meurs JC: Sine Amsler Charts: a new method for the follow-up of metamorphopsia in patients undergoing macular pucker surgery. Graefes Arch Clin Exp Ophthalmol 2003;241:89-93.
48.
Jensen OM, Larsen M: Objective assessment of photoreceptor displacement and metamorphopsia: a study of macular holes. Arch Ophthalmol 1998;116:1303-1306.
49.
Matsumoto C, Arimura E, Okuyama S, Takada S, Hashimoto S, Shimomura Y: Quantification of metamorphopsia in patients with epiretinal membranes. Invest Ophthalmol Vis Sci 2003;44:4012-4016.
50.
Arimura E, Matsumoto C, Nomoto H, Hashimoto S, Takada S, Okuyama S, Shimomura Y: Correlations between M-CHARTS and PHP findings and subjective perception of metamorphopsia in patients with macular diseases. Invest Ophthalmol Vis Sci 2011;52:128-135.
51.
Westheimer G: The spatial sense of the eye. Invest Ophthalmol Vis Sci 1979;18:893-912.
52.
Enoch JM, Williams RA, Essock EA, Barricks M: Hyperacuity perimetry. Assessment of macular function through ocular opacities. Arch Ophthalmol 1984;102:1164-1168.
53.
Goldstein M, Loewenstein A, Barak A, Pollack A, Bukelman A, Katz H, Springer A, Schachat AP, Bressler NM, Bressler SB, Cooney MJ, Alster Y, Rafaeli O, Malach R; Preferential Hyperacuity Perimeter Research Group: Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina 2005;25:296-303.
54.
Loewenstein A, Malach R, Goldstein M, Leibovitch I, Barak A, Baruch E, Alster Y, Rafaeli O, Avni I, Yassur Y: Replacing the Amsler grid: a new method for monitoring patients with age-related macular degeneration. Ophthalmology 2003;110:966-970.
55.
Wang YZ, Wilson E, Locke KG, Edwards AO: Shape discrimination in age-related macular degeneration. Invest Ophthalmol Vis Sci 2002;43:2055-2062.
56.
Wilkinson F, Wilson HR, Habak C: Detection and recognition of radial frequency patterns. Vision Res 1998;38:3555-3568.
57.
Hess RF, Wang YZ, Demanins R, Wilkinson F, Wilson HR: A deficit in amblyopia for global shape detection. Vision Res 1999;39:901-914.
58.
Wang YZ: Effects of aging on shape discrimination. Optom Vis Sci 2001;78:447-454.
59.
Hess RF, Wang YZ, Dakin SJ: Are judgments of circularity local or global? Vision Res 1999;39:4354-4360.
60.
Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A, Heier JS, Kim JE, Garfinkel RA; Appendix 1 for AREDS2-HOME Study Research Group: Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The Home Monitoring of the Eye (HOME) study design - HOME Study report number 1. Contemp Clin Trials 2014;37:294-300.
61.
Loewenstein A, Ferencz JR, Lang Y, Yeshurun I, Pollack A, Siegal R, Lifshitz T, Karp J, Roth D, Bronner G, Brown J, Mansour S, Friedman S, Michels M, Johnston R, Rapp M, Havilio M, Rafaeli O, Manor Y: Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration: multicenter evaluation of a preferential hyperacuity perimeter designed as a home device. Retina 2010;30:1058-1064.
62.
Chhetri AP, Wen FY, Wang YZ, Zhang K: Shape discrimination test on handheld devices for patient self-test; in Veinot T (ed): Proceedings of the First Annual ACM International Health Informatics Symposium (IHI 2010). Arlington, ACM Press 2010, pp 502-506.
63.
Wang YZ, He YG, Mitzel G, Zhang S, Bartlett M: Handheld shape discrimination hyperacuity test on a mobile device for remote monitoring of visual function in maculopathy. Invest Ophthalmol Vis Sci 2013;54:5497-5505.
64.
Kaiser PK, Wang YZ, He YG, Weisberger A, Wolf S, Smith CH: Feasibility of a novel remote daily monitoring system for age-related macular degeneration using mobile handheld devices: results of a pilot study. Retina 2013;33:1863-1870.
65.
Nowomiejska K, Oleszczuk A, Brzozowska A, Grzybowski A, Ksiazek K, Maciejewski R, Ksiazek P, Juenemann A, Rejdak R: M-charts as a tool for quantifying metamorphopsia in age-related macular degeneration treated with the bevacizumab injections. BMC Ophthalmol 2013;13:13.
66.
Faes L, Bodmer NS, Bachmann LM, Thiel MA, Schmid MK: Diagnostic accuracy of the Amsler grid and the preferential hyperacuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye (Lond) 2014;28:788-796.
67.
AREDS2-HOME Study Research Group, Chew EY, Clemons TE, Bressler SB, Elman MJ, Danis RP, Domalpally A, Heier JS, Kim JE, Garfinkel R: Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology 2014;121:535-544.
68.
Arimura E, Matsumoto C, Okuyama S, Takada S, Hashimoto S, Shimomura Y: Retinal contraction and metamorphopsia scores in eyes with idiopathic epiretinal membrane. Invest Ophthalmol Vis Sci 2005;46:2961-2966.
69.
Kinoshita T, Imaizumi H, Okushiba U, Miyamoto H, Ogino T, Mitamura Y: Time course of changes in metamorphopsia, visual acuity, and OCT parameters after successful epiretinal membrane surgery. Invest Ophthalmol Vis Sci 2012;53:3592-3597.
70.
Bae SH, Kim D, Park TK, Han JR, Kim H, Nam W: Preferential hyperacuity perimeter and prognostic factors for metamorphopsia after idiopathic epiretinal membrane surgery. Am J Ophthalmol 2013;155:109-117.
71.
Varano M, Scassa C, Capaldo N, Sciamanna M, Parisi V: Development of macular pseudoholes: a 36-month period of follow-up. Retina 2002;22:435-442.
72.
Arimura E, Matsumoto C, Okuyama S, Takada S, Hashimoto S, Shimomura Y: Quantification of metamorphopsia in a macular hole patient using M-CHARTS. Acta Ophthalmol Scand 2007;85:55-59.
73.
Krøyer K, Christensen U, la Cour M, Larsen M: Metamorphopsia assessment before and after vitrectomy for macular hole. Invest Ophthalmol Vis Sci 2009;50:5511-5515.
74.
Fukuda S, Okamoto F, Yuasa M, Kunikata T, Okamoto Y, Hiraoka T, Oshika T: Vision-related quality of life and visual function in patients undergoing vitrectomy, gas tamponade and cataract surgery for macular hole. Br J Ophthalmol 2009;93:1595-1599.
75.
Kim JH, Kang SW, Park DY, Kim SJ, Ha HS: Asymmetric elongation of foveal tissue after macular hole surgery and its impact on metamorphopsia. Ophthalmology 2012;119:2133-2140.
76.
Okamoto F, Sugiura Y, Okamoto Y, Hiraoka T, Oshika T: Metamorphopsia and optical coherence tomography findings after rhegmatogenous retinal detachment surgery. Am J Ophthalmol 2014;157:214-220.
77.
Wang Y, Li SY, Zhu M, Chen SJ, Liu Y, Men XH, Gillies M, Larsson J: Metamorphopsia after successful retinal detachment surgery: an optical coherence tomography study. Acta Ophthalmol Scand 2005;83:168-171.
78.
Rossetti A, Doro D, Manfrè A, Midena E: Long-term follow-up with optical coherence tomography and microperimetry in eyes with metamorphopsia after macula-off retinal detachment repair. Eye (Lond) 2010;24:1808-1813.
79.
Midena E, Vujosevic S: Visual psychophysics in diabetic retinopathy; in Tombran-Tink J, Barnstable CJ, Gardner TW (eds): Visual Dysfunction in Diabetes. Ophthalmology Research. New York, Springer, 2012, pp 69-103.
80.
Bae SW, Chae JB: Assessment of metamorphopsia in patients with central serous chorioretinopathy. Indian J Ophthalmol 2013;61:172-175.
81.
NICE Technology Appraisal Guidance 297: Ocriplasmin for Treating Vitreomacular traction. London, NICE, 2013. www.guidance.nice.org.uk/ta297.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.